1. Introduction {#j_med-2016-0066_s_001}
===============

Primary immune thrombocytopenia (ITP) is an acquired hematologic disorder characterized by isolated peripheral thrombocytopenia (platelet count \<100 x 10^9^/L) in the absence of any other underlying disease \[[@j_med-2016-0066_ref_001]-[@j_med-2016-0066_ref_005]\]. Mostly, ITP is caused by the production of autoantibodies against platelet surface markers, leading to the increase of phagocytosis by the reticuloendothelial system, mainly present in the red pulp of the spleen \[[@j_med-2016-0066_ref_004],[@j_med-2016-0066_ref_006]\]. The incidence of ITP is around 4 per 100,000 people per year \[[@j_med-2016-0066_ref_007]\] with a peak of 9 per 100,000 yearly in people over 60 years old. The yearly risk of fatal bleeding increases with age at a rate of 13% per annum for patients over 60 years old \[[@j_med-2016-0066_ref_003],[@j_med-2016-0066_ref_007]-[@j_med-2016-0066_ref_008]\]. For these reasons, the correct diagnosis and the choice of the best treatment are important for a good management of these patients. Though the criteria are simple, the diagnosis of ITP is still very challenging, especially in older patients, because of the absence of specific recommendations and the priority to exclude other diseases which can mimic ITP in the elderly, such as myelodysplastic syndromes or drug-induced ITP ([Table 1](#j_med-2016-0066_tab_001){ref-type="table"}) \[[@j_med-2016-0066_ref_003]\].

###### 

Criteria for diagnosis of ITP \[[@j_med-2016-0066_ref_004]-[@j_med-2016-0066_ref_005]\]

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Platelet count \< 100 × 10^9^/L**\
  Presence of circulating antiplatelet antibodies\
  Plasma TPO level normal or minimally elevated

  **Bleeding symptoms**: --Absent in 40% of cases, especially in younger and with platelets \> 50 × 10^9^/L--Mucocutaneous bleeding, as widespread petechiae or ecchymosis, gum bleeding, or blood blisters in mouth--Menorrhagia in women--Major bleeding as intracranial hemorrhage, more frequent in elderly with co-morbidities and/or platelets \< 30 × 10^9^/L \[[@j_med-2016-0066_ref_007]\]

  **Absence of**: Constitutional symptoms, as significant weight loss, bone pain, or night sweatsHepatosplenomegalyLymphadenopathyStigmata of congenital disorders

  **Exclusion of underlying diseases**: HCV, HIV, *H. pylori*, CMV, or VZV infectionsLiver diseaseMyelodysplastic syndromesLymphoproliferative disordersAutoimmune diseases, as systemic erythematosus lupus, antiphospholipid syndrome or Evans syndromeDrug-induced, as acetaminophen or amiodarone (for a more detailed list of drugs, see Mahévas et al. \[[@j_med-2016-0066_ref_003]\])
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations. TPO: thrombopoietin; HCV: hepatitis C virus; HIV: human immunodeficiency virus; H. pylori: Helicobacter pylori; CMV: cytomegalovirus; VZV: varicella-zoster virus.

In absence of bleeding symptoms and a platelet count \> 50 x 10^9^/L, observation alone can be preferred, while a treatment is required when platelets are less than 30 x 10^9^/L. ITP patients with platelet count from 30 to 50 x 10^9^/L are considered for treatment in the following circumstances: 1) if older than 65 year-old, 2) in the presence of bleeding symptoms or history of bleeding, 3) presence of severe comorbidities such as hypertension which may cause intracranial hemorrhage, 4) poor health-related quality of life, 5) concomitant anticoagulation therapy with antiplatelet agents, or 6) if the patient requires a surgical procedure \[[@j_med-2016-0066_ref_001],[@j_med-2016-0066_ref_003]-[@j_med-2016-0066_ref_005],[@j_med-2016-0066_ref_007],[@j_med-2016-0066_ref_009]-[@j_med-2016-0066_ref_012]\]. In all of these cases, a short-course of corticosteroids is recommended with a response rate of 70-80% \[[@j_med-2016-0066_ref_003]-[@j_med-2016-0066_ref_004],[@j_med-2016-0066_ref_007]\]. The most used drug is prednisone at 1-2 mg/Kg/day for 4 weeks, but side effects such as gastritis, hyperglycemia, psychosis, hypertension and infections are commonly reported and underestimated \[[@j_med-2016-0066_ref_003]-[@j_med-2016-0066_ref_005],[@j_med-2016-0066_ref_009],[@j_med-2016-0066_ref_013]-[@j_med-2016-0066_ref_015]\]. To minimize the corticosteroid-related complications, dexamethasone at 40 mg/day for 4 days has been used with a response rate of 50% \[[@j_med-2016-0066_ref_003],[@j_med-2016-0066_ref_005],[@j_med-2016-0066_ref_016]-[@j_med-2016-0066_ref_017]\]. In cases of very low platelet count and severe bleeding, the administration of intravenous immunoglobulin can be added at lower doses (0.4 -- 0.5 g/Kg for 4-5 days) with pre- and post-infusion hydration to reduce the risk of thrombosis, pulmonary edema and acute renal failure \[[@j_med-2016-0066_ref_003],[@j_med-2016-0066_ref_012],[@j_med-2016-0066_ref_018]-[@j_med-2016-0066_ref_022]\].

After treatment, patients could achieve a complete response (CR) or response (R), according to the criteria proposed by the International Working Group and the 2011 American Society of Hematology (ASH) guidelines, or they could experience no response (NR), or a loss of CR or R when corticosteroids are tapered or stopped ([Figure 1](#j_med-2016-0066_fig_001){ref-type="fig"}) \[[@j_med-2016-0066_ref_005]\]. In these cases, a second-line therapy, such as splenectomy, rituximab and thrombopoietin receptor agonists (TPO-RAs), may be considered to maintain a safe level of platelet count and a low risk of bleeding \[[@j_med-2016-0066_ref_004]-[@j_med-2016-0066_ref_005],[@j_med-2016-0066_ref_023]-[@j_med-2016-0066_ref_026]\]. Several studies have also shown the efficacy of danazol as a good alternative in older women with a response rate of 57-67% \[[@j_med-2016-0066_ref_003],[@j_med-2016-0066_ref_027]-[@j_med-2016-0066_ref_028]\]. Figure 12011 ASH criteria for ITP treatment response.

In this review, we focused on the role of splenectomy as second-line therapy in ITP patients and, in particular, on the effectiveness of laparoscopic splenectomy in the management of chronic ITP in older subjects.

2. Literature analysis {#j_med-2016-0066_s_002}
======================

2.1. Search strategy and inclusion and exclusion criteria {#j_med-2016-0066_s_002_s_001}
---------------------------------------------------------

Relevant literature was searched in PubMed database, from 1946 to July 2016. The key words for searches were "Splenectomy" and "Primary immune thrombocytopenia". Limiting factors were "elderly" or "adult", and "English language". Two investigators independently scanned, reviewed and chose from reference list all the potentially eligible abstracts and full text of articles for the review. Next, the eligible articles were reviewed independently for inclusion into the final analysis. Studies were included when they met the following criteria: (1) the date of publication was not earlier than 2000; (2) the article reported data collected since 1980.

From selected articles, data was collected into a standardized form for basic characteristics including publication year, source and time of cohort enrollment, study design, age, sex, number of enrolled patients divided by age and type of surgery, first-line therapies, time to splenectomy, platelet count before splenectomy, and vaccinations ([Table 2](#j_med-2016-0066_tab_002){ref-type="table"} and [3](#j_med-2016-0066_tab_003){ref-type="table"}). For the outcome the following parameters were considered: overall response rate (ORR, defined as CR+R) and relapse, the number of postoperative days, early and late complications, surgery-related mortality, red blood cell (RBC) transfusions and follow-up time.

###### 

Baseline characteristics of included studies

  Author and year                                                    Study design    Multicenter (number of centers)   Source   Number of splenectomies (Male/Female)   Patient age (years, range)   Date of cohort
  ------------------------------------------------------------------ --------------- --------------------------------- -------- --------------------------------------- ---------------------------- ----------------
  Gonzales-Porras J.R. et al., 2013 \[[@j_med-2016-0066_ref_030]\]   Retrospective   Yes (12)                          Spain    57 (27/30)                              \>65                         1982 -- 2011
  Park Y.H. et al., 2016 \[[@j_med-2016-0066_ref_029]\]              Retrospective   Yes (5)                           Korea    52 (11/41)                              66, 60-77                    1998 -- 2013

###### 

Preoperative characteristics

                               Gonzales-Porras et al.   Park et al.
  ---------------------------- ------------------------ -------------------
  Median time to splenectomy   13 months (3-54.5)       58 months (0-146)
  Number of prior treatments   2 (1-3)                  2 (1-≥)
  Operative technique                                   
  Open                         31 (54%)                 5 (9.6%)
  Laparoscopy                  26 (46%)                 47 (90.4%)
  Platelet count (×10^9^/L)    43 (16-82)               60 (2-347)
  Vaccinations                                          
  *Pneumococcus*               52 (91%)                 46 (88.5%)
  Platelet transfusion         n.r.                     9.5

2.2. Statistical Analysis {#j_med-2016-0066_s_002_s_002}
-------------------------

All data was collected from a computerized database and chart review and was analyzed using GraphPad Prism version 6.

3. Results {#j_med-2016-0066_s_003}
==========

3.1. Study selection {#j_med-2016-0066_s_003_s_001}
--------------------

A total of 2136 articles were screened and 50 of these were identified as eligible for review. We excluded 28 articles because they did not meet the selection criteria. Of the remaining 22 articles, 7 were chosen for relevance and for the use of "Laparoscopic" as limiting factor. Five articles were excluded because the median age of the cohort was less than 60 year-old or the results were not divided according to the age. [Figure 2](#j_med-2016-0066_fig_002){ref-type="fig"} shows the flow diagram for the selection process. A total of 2 articles were finally included in the analysis \[[@j_med-2016-0066_ref_029]-[@j_med-2016-0066_ref_030]\].

![Flow diagram of search strategy](j_med-2016-0066_fig_002){#j_med-2016-0066_fig_002}

3.2. Pre-operative characteristics {#j_med-2016-0066_s_003_s_002}
----------------------------------

From 1982 to 2013, a total of 109 splenectomies in older ITP patients (male/female, 38/71; age \> 60 year-old) were described in selected retrospective studies ([Table 2](#j_med-2016-0066_tab_002){ref-type="table"}), performed with open technique in 33% of cases (n=36) and laparoscopic procedure in 67% of subjects (n=73) ([Table 3](#j_med-2016-0066_tab_003){ref-type="table"}). The comorbidities were described differently in each study: as median Charlson index of 4.1 as in Gonzales-Porras et al. or as 84.6% of patients with underlying diseases (mostly cardiovascular diseases or diabetes) as in Park et al. Patients underwent splenectomy after a median time from diagnosis of 35.5 months (varying from 0 to 146 months) and a median number of prior treatments of 2 (range, 1 to more than 3). Pneumococcal vaccination was performed in 89.9% of patients (n=98) at least two weeks before surgery. The median preoperative platelet count was 51.5 x 10^9^/L (range, 2 -- 347 x10^9^/L).

3.3. Surgical procedure {#j_med-2016-0066_s_003_s_003}
-----------------------

Laparoscopic splenectomy could be performed using a lateral or anterior approach, preferred for very large spleens. The operation starts with safe laparoscopic abdominal access using open or closed technique with a Verres needle (contraindicated in patients with massive splenomegaly and severe thrombocytopenia). Once the peritoneal cavity is accessed, 4-5 trocars are positioned: the first (5 or 12 mm port) in the midclavicular line at 2-6 cm below the costal margin; the second medial trocar in the midline subxiphoid region in the left subcostal position; the third in the anterior axillary line in the left subcostal region; the fourth laterally off the tip of the 11^th^ rib. The port with the best angle for hilar ligation could be used as a 12 mm port for the endoscopic stapler and for the extraction of the spleen. Preliminary to the procedure, accessory spleens have to be looked for in the hilum, omentum, mesocolon or mesentery. Dissection starts from the inferior pole of the spleen with the section of the splenocolic, splenorenal and gastrosplenic ligaments. After this, the splenic hilum is accessible and the splenic artery can be controlled, proximal to the splenic hilum (1-2 cm), along the superior border of the pancreas; otherwise the splenophrenic ligament can be divided superiorly. Then the hilum is carefully dissected from the tail of pancreas and splenopancreatic ligament. Now, the splenic vasculature can be ligated and divided and the spleen can be grasped from the splenocolic ligament left on the inferior border and flipped with the hilum facing up. The spleen is ready to be placed in a retrievable sac and morcellated, unless the spleen must be removed intact for pathologic analysis. During the morcellation phase, it is important to not break the bag and spill the splenic tissue into the peritoneal cavity. When the morcellation cannot be performed, the spleen could be removed through a Pfannenstiel suprapubic access. After removal, hemostasis must be evaluated; suction drains are placed, the abdomen is reinsufflated and the skin incisions are closed \[[@j_med-2016-0066_ref_031]-[@j_med-2016-0066_ref_038]\].

3.4. Outcome and complication rate {#j_med-2016-0066_s_003_s_004}
----------------------------------

Splenectomized patients experienced a median postoperative stay of 8 days (range, 4--52 days). The median follow-up was 60 months (range, 0--146 months). Using the 2011 ASH criteria for ITP treatment response, 73 patients (67%) achieved a complete response (CR) after splenectomy and 14 subjects (13%) a response (R), for an overall response rate (ORR) of 80%. Nineteen percent of patients (n=21) did not respond to treatment, and 39% (n=43) relapsed after surgery ([Table 4](#j_med-2016-0066_tab_004){ref-type="table"}).

###### 

Response after splenectomy

                       Gonzales-Porras et al.   Park et al.
  -------------------- ------------------------ -------------
  Postoperative days   8 (6-14)                 9.5 (4-52)
  CR (%)               41 (71.9)                32 (61.5)
  R (%)                4 (7)                    10 (19.2)
  ORR (%)              45 (78.9)                42 (80.7)
  NR (%)               12 (7.5)                 9 (17.3)
  Relapse (%)          24 (42.9)                19 (45.2)
  Follow-up (months)   62 (27-113)              58 (0-146)
  PFS (months)         \>42                     3

**Abbreviations**. CR: complete response; R: response; ORR: overall response rate; NR: no response; PFS: progression-free survival.

Operative mortality was assessed at 2% (n=2), but one death was related to an intracranial hemorrhage 5 days post-splenectomy. The complication rate was 48% (n=52) and early or late bleeding was the most frequent complication (48% of all postoperative events, n=25). Other frequent complications were infections (29%, n=15), late thrombotic events (13%, n=7), and subphrenic abscess (8%, n=4). Cardiovascular events were reported at very low frequency (2%, n=1 as paroxysmal atrial fibrillation).

Red blood cell transfusions were performed in a median of 16 splenectomized patients (0-16) ([Table 5](#j_med-2016-0066_tab_005){ref-type="table"} and [Figure 3](#j_med-2016-0066_fig_003){ref-type="fig"}).

![Complication rate in elderly splenectomized ITP patients.](j_med-2016-0066_fig_003){#j_med-2016-0066_fig_003}

###### 

Postoperative complications

                             Gonzales-Porras et al.   Park et al.
  -------------------------- ------------------------ -------------
  Any complications          31                       21
     Bleeding                16                       9
     Infections              11                       4
     Cardiovascular events   0                        1
     Subphrenic abscess      3                        1
     Thrombotic events       1                        6
  RBC transfusion            16                       0 (0-10)
  Operative mortality        1                        1

**Abbreviations**. RBC: red blood cells.

4. Discussion {#j_med-2016-0066_s_004}
=============

Diagnosis and management of ITP are still very challenging in older patients because of the lack of guidelines \[[@j_med-2016-0066_ref_003],[@j_med-2016-0066_ref_039]-[@j_med-2016-0066_ref_041]\]. Treatment is required for patients older than 65 years with a platelet count less than 50 x 10^9^/L, and/ or when bleeding symptoms, severe comorbidities, severe disabilities or anticoagulation therapy are reported \[[@j_med-2016-0066_ref_003]\]. First-line therapies include short-course corticosteroids with or without low-dose intravenous immunoglobulins (IVIg), but are not effective for a sustained response, since most patients relapse after tapering off or stopping therapy \[[@j_med-2016-0066_ref_004]-[@j_med-2016-0066_ref_005],[@j_med-2016-0066_ref_023]-[@j_med-2016-0066_ref_026],[@j_med-2016-0066_ref_039]-[@j_med-2016-0066_ref_041]\]. For this reason, adult, especially elderly, ITP patients develop chronic ITP with a very-high yearly risk of fatal bleeding \[[@j_med-2016-0066_ref_003],[@j_med-2016-0066_ref_007]-[@j_med-2016-0066_ref_008]\]. International guidelines equally suggest the use of splenectomy, rituximab and TPO-RAs as second-line therapy, with the option to switch from one to another in case the previous treatment should fail \[[@j_med-2016-0066_ref_004]-[@j_med-2016-0066_ref_005],[@j_med-2016-0066_ref_023]-[@j_med-2016-0066_ref_026],[@j_med-2016-0066_ref_039]-[@j_med-2016-0066_ref_045]\].

Given the increasingly frequent use of less invasive techniques, such as the fine-needle aspiration biopsy, splenectomy is less and less used in malignant hematological disorders for diagnostic purposes \[[@j_med-2016-0066_ref_046]-[@j_med-2016-0066_ref_051]\], but is still used for palliation or to facilitate drug therapy \[[@j_med-2016-0066_ref_043]-[@j_med-2016-0066_ref_045]\]. Conversely, splenectomy so far is a key treatment option in hematological benign disorders such as ITP, autoimmune hemolytic anemia, hereditary spherocytosis and some types of hemoglobinopathies and thalassemia \[[@j_med-2016-0066_ref_045]\]. Among the benign hematological disorders, one of the most frequent indications for splenectomy is definitely ITP \[[@j_med-2016-0066_ref_042],[@j_med-2016-0066_ref_045]\]. In children, the 2011 ASH guidelines recommend delaying splenectomy until the chronic phase (\>12 months), unless severe disease is unresponsive to other treatments or causes a poor quality of life \[[@j_med-2016-0066_ref_004],[@j_med-2016-0066_ref_005]\]. Together with the higher postoperative complication rate and mortality of major surgery in adults due to comorbidities, splenectomy is usually the third choice in elderly patients and is delayed for longer than the recommended 12 months (median, 35.5 months), as we highlighted in the two selected studies \[[@j_med-2016-0066_ref_029],[@j_med-2016-0066_ref_030]\].

Several reviews reported a complete remission rate (CRr) after splenectomy of 66% at 28 months (range, 1 -- 153 months) in children and adults, or of 64% at 7.25 years (range, 5 -- 12.75 years) only in adults, or of 72% at 5 years only in patients who received laparoscopic splenectomy. Two limitations of this data set are the definition of "adult" which contains a wide range of patients up to 18 years old and the combination of data from children and adults \[[@j_med-2016-0066_ref_042]\]. The two studies included in our series focused on small cohorts of patients older than 60 years but CRr and ORR were similar to the general splenectomized population (67% at 60 months and 80% vs 88% of all splenectomies, respectively). Gonzales-Porras et al. and Park et al. described a relapse rate in elderly patients of 39%, 2.5-fold higher than the general splenectomized population (15%; range, 0 -- 51%) \[[@j_med-2016-0066_ref_029],[@j_med-2016-0066_ref_030]\]. Therefore, these findings suggest that splenectomies in elderly patients could not be used a "definitive" treatment as it is in younger patients \[[@j_med-2016-0066_ref_042]\]. On the other hand, the authors suggested that the higher relapse rate is negatively influenced by the older age (\>65 year-old) and lack of response to prior treatments \[[@j_med-2016-0066_ref_029],[@j_med-2016-0066_ref_030]\]. Indeed, several studies showed that an age of \< 50 years old and the response to previous therapies are favorable predictive factors for hematological remission after splenectomy \[[@j_med-2016-0066_ref_006],[@j_med-2016-0066_ref_042]\]. Gonzales-Porras et al. confirmed these reports because the highest relapse rate was found in older patients who received several treatments before splenectomy. The 30-day mortality in laparoscopic and open splenectomy was assessed at 0.2% and 1% respectively in the general ITP population, similar to the rate observed in our series of older patients (1%), and is not related to the type of surgery \[[@j_med-2016-0066_ref_042]\].

Due to their comorbidities, mostly diabetes and cardiovascular diseases, older patients more frequently experience postoperative complications, which may negatively affect the outcome regardless of the underlying disease \[[@j_med-2016-0066_ref_003],[@j_med-2016-0066_ref_052]-[@j_med-2016-0066_ref_054]\]. The complication rate in all splenectomies was assessed at 9.6% for laparoscopy and 12.9% for laparotomy, 10- and 4-fold lower respectively than the reported older cohorts \[[@j_med-2016-0066_ref_042]\]. Early and late bleedings are the most frequent complications in younger, adult and older patients, and the risk was not related to the use of anti-aggregation agents \[[@j_med-2016-0066_ref_003],[@j_med-2016-0066_ref_042]\]. Interestingly, in older ITP patients, the infection rate was 13.8%, higher than the 3-10% of all splenectomies, even if 89.9% of patients received at least pneumococcal immunization prior to surgery \[[@j_med-2016-0066_ref_003],[@j_med-2016-0066_ref_055]\]. These findings support the hypothesis that splenectomy deregulates the immune system which becomes less efficient at removing encapsulated bacteria or other pathogenic particles in peripheral blood, increasing the frequency of recurrent bacterial and viral infections and the risk of overwhelming sepsis \[[@j_med-2016-0066_ref_054]\]. This susceptibility may be highlighted in elderly patients because of their comorbidities and older age, explaining the higher infection rate reported in this population after splenectomy. Thromboembolic events represent the most frequent late complications: up to 70% of splenectomized patients experienced a portal vein thrombosis of unknown clinical significance, because in most cases therapy was not necessary \[[@j_med-2016-0066_ref_002],[@j_med-2016-0066_ref_056]\]. Major events were documented in 10% of all cases, as well as in elderly cases (6%) \[[@j_med-2016-0066_ref_042]\].

As favorable predictive factors for response to splenectomy, several studies suggest the use of preoperative platelet count, though Gonzales-Porras et al. did not report a significant correlation between higher preoperative platelet count and complete remission after splenectomy \[[@j_med-2016-0066_ref_006],[@j_med-2016-0066_ref_029]-[@j_med-2016-0066_ref_030]\]; instead a higher postoperative platelet count may better predict the hematological response after surgery \[[@j_med-2016-0066_ref_029]\].

5. Conclusion {#j_med-2016-0066_s_005}
=============

The management of older patients with chronic ITP is still challenging because of the presence of severe comorbidities and/or disabilities that influence the choice of the best treatment, which becomes a compromise between effectiveness and safety. As second-line therapy, laparoscopic or open splenectomy could be chosen as "curative" strategy in younger patients and women who contemplate pregnancy with higher complete response rates and low complication frequencies. Older patients undergoing splenectomy already have unfavorable conditions (age \>60 year-old, presence of comorbidities, or multiple previous treatments) which negatively influence the outcome, increasing the relapse and complication rates. For these reasons, a good management of concomitant diseases and the option not to use splenectomy as the last possible chance could improve the outcome of older splenectomized patients who, nevertheless, show a response rate similar to general ITP population after surgery. However, these results require further validation in prospective or randomized larger studies.
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